Currently out of the existing stock ratings of Andrew Baum, 26 are a HOLD (35.62%), 45 are a BUY (61.64%), 2 are a SELL (2.74%).

Andrew Baum

Work Performance Price Targets & Ratings Chart

Analyst Andrew Baum, currently employed at CITI, carries an average stock price target met ratio of 55.05% that have a potential upside of 22.54% achieved within 413 days.

Andrew Baum’s has documented 149 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRK, Merck mpany at 13-May-2025.

Wall Street Analyst Andrew Baum

Analyst best performing recommendations are on LLY (ELI LILLY AND COMPANY).
The best stock recommendation documented was for LLY (ELI LILLY AND COMPANY) at 7/26/2023. The price target of $525 was fulfilled within 19 days with a profit of $78.81 (17.66%) receiving and performance score of 9.3.

Average potential price target upside

of $39.61 (22.87%) on LLY (ELI LILLY AND COMPANY).
of $35.31 (50.65%) on NVS (NOVARTIS AG ADR).
of $29.34 (42.87%) on ABBV (ABBVIE).

ABBV AbbVie AZN AstraZeneca PLC ADR BMY Bristol-Myers Squibb Company LLY Eli Lilly and Company MRK Merck mpany PFE Pfizer GSK GlaxoSmithKline PLC ADR RPRX Royalty Pharma Plc ALVO Alvotech NVS Novartis AG ADR RHHBY Roche Holding Ltd ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Vamil Divan (GUGGENHEIM)